| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
62,898 |
58,032 |
$4.52M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
30,724 |
27,907 |
$2.92M |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
30,461 |
27,834 |
$736K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
11,760 |
11,055 |
$668K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
5,202 |
4,842 |
$375K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
32,091 |
14,356 |
$277K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
8,495 |
7,415 |
$245K |
| 87807 |
|
3,799 |
3,487 |
$31K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,035 |
1,781 |
$26K |
| 87430 |
|
887 |
660 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
560 |
503 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
327 |
292 |
$5K |
| 87501 |
|
583 |
456 |
$2K |
| 81002 |
|
471 |
415 |
$887.94 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
37 |
32 |
$581.07 |
| 87420 |
|
195 |
161 |
$521.52 |
| 81003 |
|
233 |
226 |
$383.81 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
664 |
624 |
$106.61 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
58 |
51 |
$76.33 |
| 94760 |
|
629 |
557 |
$65.34 |
| 94761 |
|
33 |
29 |
$19.97 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
45 |
40 |
$1.59 |